Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.
about
Generation of superoxide anion radicals and platelet glutathione peroxidase activity in patients with schizophrenia.Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial.Decreased mean platelet volume in panic disorder.Phyllostachys edulis extract induces apoptosis signaling in osteosarcoma cells, associated with AMPK activationAnxiety and depression levels in prepubertal obese children: a case-control study.Microemulsion of babassu oil as a natural product to improve human immune system function.Self-concept evaluation and migraine without aura in childhoodTemperamental characteristics in childhood migraine without aura: a multicenter studyMaternal personality profile of children affected by migraine.Attachment styles in children affected by migraine without aura.Pediatric neurofibromatosis 1 and parental stress: a multicenter studyNeurofibromatosis type 1 and attention deficit hyperactivity disorder: a case study and literature reviewOrthodontic treatment need for adolescents in the Campania region: the malocclusion impact on self-concept.Treatment of neurofibromatosis type 1.Effectiveness and safety of Nintendo Wii Fit Plus™ training in children with migraine without aura: a preliminary study.Visual-spatial training efficacy in children affected by migraine without aura: a multicenter studyPsychomotor approach in children affected by nonretentive fecal soiling (FNRFS): a new rehabilitative purpose.Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 Patients.The Rorschach Test Evaluation in Chronic Childhood Migraine: A Preliminary Multicenter Case–Control Study.
P2860
Q33589462-5DB7DDC2-EC5D-4155-B8D9-00A25A651FF3Q33606202-0FDC2788-F7E7-42BE-9B4A-C3F17B514B23Q34156457-5DA4C0A5-ACD9-4BA6-B7B8-F9864615864DQ34273651-58B2EA48-3E08-4F2E-A3B9-4327F9162D75Q34354412-F8BB0EDC-1C6C-4AA2-9B80-53DF3E7FF53DQ34757152-6703360B-0351-4DA7-BAE8-46D5C8E0444BQ37092291-F137818B-7AF1-43F3-AB68-7FFA01BE4EA8Q37106859-EEEC9511-53DC-4B8D-881D-A924442B9E94Q37178812-F988111A-D89C-4426-BDD7-87F080334CCEQ37225584-D61A59B4-6B46-4453-9496-9788BF7A032CQ37524978-0E5A14A8-F71D-4D39-99E9-8BD1994810CAQ38408760-E099856B-22C7-43DE-BC67-4D8D1FFF4FFDQ38455787-31F6E3C8-74D2-4BBF-80E8-9BE698D0BCA3Q41008080-3F60086D-BFB8-44E6-9498-BF6FCBF328F6Q41870157-A45FE00A-F06C-4EFD-B53E-780A25689BDCQ41938930-7CA564B0-BE40-494F-8229-AD8CFD95FB29Q42182474-02FC7362-276E-4FAD-A947-F2BC3274EC45Q42340618-68EB6038-2D17-4724-96D6-66148A4732A9Q47176801-169C6556-D4AA-4097-A378-A1AE5D6F7E45
P2860
Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Nutraceuticals safety and effi ...... d by neurofibromatosis type I.
@en
Nutraceuticals safety and effi ...... d by neurofibromatosis type I.
@nl
type
label
Nutraceuticals safety and effi ...... d by neurofibromatosis type I.
@en
Nutraceuticals safety and effi ...... d by neurofibromatosis type I.
@nl
prefLabel
Nutraceuticals safety and effi ...... d by neurofibromatosis type I.
@en
Nutraceuticals safety and effi ...... d by neurofibromatosis type I.
@nl
P2860
P1476
Nutraceuticals safety and effi ...... d by neurofibromatosis type I.
@en
P2860
P2888
P304
P356
10.1007/S10072-013-1403-Z
P577
2013-03-27T00:00:00Z